Travere Therapeutics (TVTX) is drawing attention after reporting strong U.S. net product sales growth driven by FILSPARI and outlining expectations for a US$25 million sales based milestone payment from Mirum Pharmaceuticals in early 2026.

The recent update on FILSPARI sales and the expected Mirum milestone comes after a tough stretch for the share price, with a year to date share price return of negative 26.67% and a 90 day share price return of negative 16.02%. This is in contrast to the 1 year total shareholder return of 62.17% and 3 year total shareholder return of 33.36%, suggesting long term holders have seen very different outcomes from short term traders around the current US$28.98 level.

If this kind of biotech news has your attention, it could be a good time to see what else is out there through our screener of 32 healthcare AI stocks. You might find a few fresh ideas to research next.

With Travere shares down year to date despite annual revenue growth of 20.22% and an annual improvement in net income of 49.81%, while also trading at a 47% discount to analyst targets, investors may question whether this represents a potential entry point or if the market is already accounting for future growth.

Most Popular Narrative: 31.6% Undervalued

Travere's most followed narrative sets a fair value of $42.36 per share against the latest close at $28.98, framing a clear valuation gap for investors to think about.

Travere's strengthening financial position, driven by rapid product sales growth, increased international out-licensing revenues, significant reductions in net losses, and prudent R&D and SG&A management, sets a foundation for positive net earnings while securing resources for continued pipeline development and future commercial launches. (Earnings, cash flow, R&D investment)

Want to see how this story translates into numbers? Revenue, margins and future earnings power are all wired into this fair value. The full narrative lays out the math behind that $42.36 figure.

Result: Fair Value of $42.36 (UNDERVALUED)

However, this hinges on FILSPARI maintaining its edge in a crowded kidney space and on the FSGS review process not slipping or tightening unexpectedly.

Next Steps

With the mix of risks and rewards you have just read about, it makes sense to check the numbers yourself and decide where you stand. Our breakdown of 5 key rewards and 1 important warning sign can help you weigh both sides quickly.

Looking for more investment ideas?

If this update has you thinking bigger than a single stock, now is the moment to widen your watchlist and hunt for ideas that truly fit your approach.

• Target potential mispricings by scanning 46 high quality undervalued stocks that might offer a more attractive entry point than what is already on your radar.
• Lock in potential income ideas by reviewing a curated set of 14 dividend fortresses that focus on higher yields with staying power.
• Stay on the front foot by checking our 63 resilient stocks with low risk scores that prioritize resilience when conditions get choppy.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.